The evaluation of the anti-cancer activity of ixazomib on Caco2 colon solid tumor cells, comparison with bortezomib

References

• Faivre J, Bouvier A, Bonithon-Kopp C. Epidemiology and screening of colorectal cancer. Best Pract Res Clin Gastroenterol. 2002;16:187–99.10.1053/bega.2001.0280
   PubMed Web of Science ®Google Scholar
• Voutsadakis A, Patrikidou A, Tsapakidis K, Karagiannaki A, Hatzidaki E, Stathakis N, et al. Additive inhibition of colorectal cancer cell lines by aspirin and bortezomib. Int J Colorectal Dis. 2010;25:795–804.10.1007/s00384-010-0939-0
   PubMed Web of Science ®Google Scholar
• Voutsadakis I. Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin-proteasome system and Cox-2. J Cell Mol Med. 2007;11:252–85.10.1111/jcmm.2007.11.issue-2
   PubMed Web of Science ®Google Scholar
• Chauhan D, Tian Z, Zhou B, Kuhn D, Orlowski R, Raje N, et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res. 2011;17(16):5311–21.10.1158/1078-0432.CCR-11-0476
   PubMed Web of Science ®Google Scholar
• Roy SS, Kirma NB, Santhamma B, Tekmal RR, Agyin JK. Effects of a novel proteasome inhibitor BU-32 on multiple myeloma cells. Cancer Chemother Pharmacol. 2014;73:1263–71.10.1007/s00280-014-2463-3
   PubMed Web of Science ®Google Scholar
• Anderson KC. New insights into therapeutic targets in myeloma. Hematology. 2011; 184–90.10.1182/asheducation-2011.1.184
   PubMed Web of Science ®Google Scholar
• Chauhan D, Singh AV, Aujay M, Kirk CJ, Bandi M, Ciccarelli B, et al. A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood. 2010;116:4906–15.10.1182/blood-2010-04-276626
   PubMed Web of Science ®Google Scholar
• Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 2012;120:947–59.10.1182/blood-2012-04-403733
   PubMed Web of Science ®Google Scholar
• Dick LR, Fleming PE. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov Today. 2010;15:243–9.10.1016/j.drudis.2010.01.008
   PubMed Web of Science ®Google Scholar
• Kupperman E, Lee EC, Cao Y, Bannerman B, Fitzgerald M, Berger A, et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res. 2010;70:1970–80.10.1158/0008-5472.CAN-09-2766
   PubMed Web of Science ®Google Scholar
• Allegra A, Alonci A, Gerace D, Russo S, Innao V, Calabrò L, Musolino C. New orally active proteasome inhibitors in multiple myeloma. Leuk Res. 2014;38:1–9.10.1016/j.leukres.2013.10.018
   PubMed Web of Science ®Google Scholar
• Engür S, Dikmen M, Öztürk Y. Comparison of antiproliferative and apoptotic effects of a novel proteasome inhibitor MLN2238 with bortezomib on K562 chronic myeloid leukemia cells. Immunopharmacol Immunotoxicol. 2016;38:87–97.
   PubMed Web of Science ®Google Scholar
• Dikmen M, Canturk Z, Ozturk Y, Tunali Y. Investigation of the apoptotic effect of curcumin in human leukemia HL-60 cells by using flow cytometry. Cancer Biother Radiopharm. 2010;25:749–55.10.1089/cbr.2010.0822
   PubMed Web of Science ®Google Scholar
• Kim DY, Hwang YJ. Effects of ginsenoside-Rg₁ on post-thawed miniature pig sperm motility, mitochondria activity, and membrane integrity. J Embryo Transfer. 2013;28:63–71.
   Google Scholar
• Kabadere S, Kus G, Uyar R, Oztopcu-Vatan P. Licofelone abolishes survival of carcinogenic fibroblasts by inducing apoptosis. Drug Chem Toxicol. 2013;37(1):1–7.
   PubMed Web of Science ®Google Scholar
• Kus G, Oztopcu-Vatan P, Uyar R, Kabadere S. Cytotoxic and apoptotic functions of licofelone on rat glioma cells. Acta Biol Hung. 2013;64(4):438–52.10.1556/ABiol.64.2013.4.4
   PubMed Web of Science ®Google Scholar
• Teicher BA, Tomaszewski JE. Proteasome inhibitors. Biochem Pharmacol. 2015;96:1–9.10.1016/j.bcp.2015.04.008
   PubMed Web of Science ®Google Scholar
• Johnson Daniel E. The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors. Endocr Relat Cancer. 2015;22(1):1–17.10.1530/ERC-14-0005
   PubMed Web of Science ®Google Scholar
• Liu X, Yue P, Chen S, Hu L, Lonial S, Khuri FR, et al. The proteasome ınhibitor PS-341 (Bortezomib) up-regulates DR5 expression leading to ınduction of apoptosis and enhancement of TRAIL-ınduced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res. 2007;67:4981–8.10.1158/0008-5472.CAN-06-4274
   PubMed Web of Science ®Google Scholar
• Li C, Li R, Grandis JR, Johnson DE. Bortezomib induces apoptosis via Bim and Bik up-regulation and synergizes with cisplatin in the killing of head and neck squamous cell carcinoma cells. Mol Cancer Ther. 2008;7:1647–55.10.1158/1535-7163.MCT-07-2444
   PubMed Web of Science ®Google Scholar
• Chen KF, Yeh PY, Hsu C, Hsu CH, Lu YS, Hsieh HP, et al. Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the ınhibition of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem. 2009;284:11121–33.10.1074/jbc.M806268200
   PubMed Web of Science ®Google Scholar
• Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V, et al. Proteasome ınhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res. 2005;65:6282–6293.10.1158/0008-5472.CAN-05-0676
   PubMed Web of Science ®Google Scholar
• Nikrad M, Johnson T, Puthalalath H, Coultas L, Adams J, Kraft AS. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol Cancer Ther. 2005;4:443–9.
   PubMed Web of Science ®Google Scholar
• Zhu H, Guo W, Zhang L, Wu S, Teraishi F, Davis JJ, et al. Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation. Cancer Biol Ther. 2005;4:781–6.10.4161/cbt.4.7.1897
   PubMed Web of Science ®Google Scholar
• Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 11:21–28.
   PubMed Web of Science ®Google Scholar
• Nawrocki ST, Bruns CJ, Harbison MT, Bold RJ, Gotsch BS, Abbruzzese JL, et al. Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther. 2002;1:1243–53.
   PubMed Web of Science ®Google Scholar
• Pitts TM, Morrow M, Kaufman SA, Tentler JJ, Eckhardt SG. Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models. Mol Cancer Ther. 2009;8(2):342–9.10.1158/1535-7163.MCT-08-0534
   PubMed Web of Science ®Google Scholar
• Milano A, Iaffaioli RV, Caponigro F. The proteasome: a worthwhile target for the treatment of solid tumours?. Eur J Cancer. 2007;43:1125–33.10.1016/j.ejca.2007.01.038
   PubMed Web of Science ®Google Scholar
• Yang X. Proteasome inhibitor bortezomi-induced the apoptosis of laryngeal squamous cell carcinoma Hep-2 cell line via disrupting redox equilibrium. Biomed Pharmacother. 2012;66(8):607–11.10.1016/j.biopha.2012.08.010
   PubMed Web of Science ®Google Scholar
• Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999;59:2615–22.
   PubMed Web of Science ®Google Scholar
• Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY, Cheng AL. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res. 2008;68:6698–707.10.1158/0008-5472.CAN-08-0257
   PubMed Web of Science ®Google Scholar
• Jones MD, Liu JC, Barthel TK, Hussain S, Lovria E, Cheng D, et al. A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes. Clin Cancer Res. 2010;16:4978–89.10.1158/1078-0432.CCR-09-3293
   PubMed Web of Science ®Google Scholar
• Brüning A, Burger P, Vogel M, Rahmeh M, Friese K, Lenhard M, et al. Bortezomib treatment of ovarian cancer cells mediates endoplasmic reticulum stress, cell cycle arrest, and apoptosis. Invest New Drugs. 2009;27:543–51.10.1007/s10637-008-9206-4
   PubMed Web of Science ®Google Scholar
• Williams S, Pettaway C, Song R, Papandreou C, Logothetis C, McConkey DJ. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther. 2003;2:835–43.
   PubMed Web of Science ®Google Scholar
• Hong YS, Hong SW, Kim SM, Jin DH, Shin JS, Yoon DH, et al. Bortezomib induces G2-M arrest in human colon cancer cells through ROS-inducible phosphorylation of ATM-CHK1. Int J Oncol. 2012;41:76–82.
   PubMed Web of Science ®Google Scholar
• Lin YC, Chen KC, Chen CC, Cheng AL, Chen KF. CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells. Oral Oncol. 2012;48:585–93.10.1016/j.oraloncology.2012.01.012
   PubMed Web of Science ®Google Scholar
• Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res. 1999;5:2638–45.
   PubMed Web of Science ®Google Scholar
• Krętowski R, Stypułkowska A, Cechowska-Pasko M. Efficient apoptosis and necrosis induction by proteasome inhibitor: bortezomib in the DLD-1 human colon cancer cell line. Mol Cell Biochem. 2015;398(1–2):165–73.10.1007/s11010-014-2216-y
   PubMed Web of Science ®Google Scholar
• Crawford LJ, Walker B, Irvine AE. Proteasome inhibitors in cancer therapy. J. Cell Commun Signal. 2011;5:101–110.10.1007/s12079-011-0121-7
   PubMed Web of Science ®Google Scholar
• Pajonk F, McBride WH. The proteasome in cancer biology and treatment. Radiat Res. 2001;156:447–59.10.1667/0033-7587(2001)156[0447:TPICBA]2.0.CO;2
   PubMed Web of Science ®Google Scholar
• Luqman BS, Pezzuto JM. NFkappaB: a promising target for natural products in cancer chemoprevention. Phytother Res. 2010;24:949–63.
   PubMed Web of Science ®Google Scholar
• Frankland-Searby S, Bhaumik RS. The 26S proteasome complex: an attractive target for cancer therapy. Biochim Biophys Acta. 2012;1825:64–76.
   PubMed Web of Science ®Google Scholar
• Terzić J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology. 2010;138:2101–14.10.1053/j.gastro.2010.01.058
   PubMed Web of Science ®Google Scholar
• Miller DM, Thomas SD, Islam A, Muench D, Sedoris K. c-Myc and cancer metabolism. Clin Cancer Res. 2012;18:5546–53.10.1158/1078-0432.CCR-12-0977
   PubMed Web of Science ®Google Scholar
• Thompson EB. The many roles of c-Myc in apoptosis. Annu Rev Physiol. 1998;60:575–600.10.1146/annurev.physiol.60.1.575
   PubMed Web of Science ®Google Scholar
• Lashinger LM, Zhu K, Williams SA. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Cancer Res. 2005;65:4902–8.10.1158/0008-5472.CAN-04-3701
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Richardson P. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002;277:16639–16647.
   PubMed Web of Science ®Google Scholar